Forward Pharma is a privately held biotechnology company, founded in 2005 in Copenhagen, Denmark. The company is focused on the immunomodulatory compound dimethyl fumarate and derivatives, for applications as pharmaceutical drug product in lead areas of dermatology, neurology and oncology.
FP187 (dimethyl fumarate) is Forward Pharma’s oral fumaric acid ester (FAE) late-stage clinical product candidate in psoriasis and multiple sclerosis.
Prof. Dr. Kristian Reich on fumaric acid ester (FAE) therapy in psoriasis, Hamburg, 15.08.2012
Mr. J. Kevin Buchi, former CEO of Cephalon Inc., has been appointed to the Board of Directors of Forward Pharma A/S.
Forward Pharma has completed its pivotal registration study for its primary development compound FP187.
Science of dimethyl fumarate
Dimethyl fumarate – only an anti-psoriatic medication? Meissner M et al., JDDG 2012. Link
Dimethyl Fumarate Inhibits Dendritic Cell Maturation via NF-kB and ERK1/2 and MSK1 Signaling. Peng H et al., JBC 2012. Link
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. Ghoreschi K et al., J Exp Med 2011. Link
Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy. Salgo R et al., Exp Dermatol. 2011. Link
Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression. Gesser B et al., Inflamm. Res. 2011. Link